title: AGI report focuses on unanswered Norplant questions.
mesh_terms: D000554:Ambulatory Care Facilities; D000569:Americas; D003132:Commerce; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003362:Cost-Benefit Analysis; D003376:Counseling; D019049:Developed Countries; D004467:Economics; D005069:Evaluation Studies as Topic; D005193:Family Planning Services; D006285:Health Planning; D016912:Levonorgestrel; D009656:North America; D014481:United States
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D016912:Levonorgestrel
keywords: Americas; Clinic Activities; Commerce; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Implants; Contraceptive Methods; Cost Effectiveness; Counseling; Critique; Developed Countries; Economic Factors; Evaluation Indexes; Family Planning; Levonorgestrel; Macroeconomic Factors; North America; Northern America; Prices; Program Activities; Programs; Quantitative Evaluation; United States